The company said, “Teknova is reiterating its fiscal 2024 outlook for revenue and free cash outflow. The Company continues to anticipate total revenue of $35 million to $38 million for the fiscal year ending December 31, 2024 (“2024″), which assumes roughly 10% growth in Lab Essentials and the remaining revenue from Clinical Solutions. The Company also continues to anticipate free cash outflow of less than $18 million for 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TKNO: